Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer
NCT ID: NCT01755130
Last Updated: 2021-06-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
9 participants
INTERVENTIONAL
2014-05-13
2021-06-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts
NCT02042456
Breast Density and the Role of Preoperative Mammography, Ultrasound, Elastography and MRI
NCT00695968
Combined Digital X-ray and Ultrasound Technique for Improved Detection and Characterization of Breast Lesions
NCT00721435
Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients
NCT04440982
Multi-Compression Spot Mammography
NCT01372215
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To successfully obtain images from laser optoacoustic and ultrasonic imaging system assembly (LOUISA) 3-dimensional (3D) and assess pathology in order to guide image calibration and gain knowledge about LOUISA 3D capabilities to detect and differentiate breast tumors.
II. Estimate and compare the false positive rate of LOUISA-3D compared to standard of care ultrasound for detecting breast cancer in year 5 of the study.
SECONDARY OBJECTIVES:
I. Determine optimal scanning parameters by assessing certain machine parameters (e.g. illumination and detection conditions, laser pulse repetition rate, laser ultrasound emission characteristics, type of imaging probe, two-dimensional images vs three-dimensional images, coupling medium characteristics, software and firmware, etc.), anatomical information (speed of sound image, acoustic attenuation image, acoustic scattering image), and functional information (total hemoglobin distribution \[THb\]/image of angiogenesis density, image of blood oxygen saturation \[SO2\], and image of water distribution).
OUTLINE:
Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Diagnostic (LOUISA 3D)
Patients undergo LOUISA 3D over approximately 30 minutes on the same day or within 7 days of any breast imaging procedure and within 7 days before biopsy.
Photoacoustic Imaging
Undergo LOUISA 3D
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Photoacoustic Imaging
Undergo LOUISA 3D
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tissue density - all tissue types
* Menses - any stage of cycle
* Suspicious breast mass(es) defined by mammography or ultrasound indicating biopsy is needed (biopsy not needed if previous biopsy results are available on target lesion\[s\])
* Tumor location - the mammography or ultrasound report should not say that the tumor is in close proximity of chest wall
* Any tumor type (patients with inflammatory breast cancer may be included)
Exclusion Criteria
* Disability (psychiatric, neurological or physical, which precludes examination)
* Patient has tattoos on the region of interest
* Overweight over 250 pounds (LB)
* Very large breast size exceeding 6 inch diameter
* Patient has body piercing jewelry through the nipple that cannot be removed
* Patient has had a core or excisional biopsy in the ipsilateral breast within the last 2 weeks (patients with previous fine needle aspirations but no ultrasound evidence of hematoma or post biopsy \[bx\] change may be included)
* Patient has inflammatory skin disease (i.e., psoriasis, eczema) or other irritation affecting the breast
* Patient has any pain or high sensitivity in the breast
* Currently taking hormonal replacement therapy
* Non-ambulatory or unable to comply with exam
* Pregnant (pregnancy test is not required, only as confirmed by patient)
* Breastfeeding
* Prior breast treatment for target lesion
* Previous surgery of the breast in the last 3 months
20 Years
85 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Yang
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
M D Anderson Cancer Center
Houston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2014-01243
Identifier Type: REGISTRY
Identifier Source: secondary_id
NCI-2013-00149
Identifier Type: -
Identifier Source: secondary_id
2012-0210
Identifier Type: OTHER
Identifier Source: secondary_id
2012-0210
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.